Radiotherapy With Cisplatin or Panitumumab in Head and Neck Carcinoma—Reply

In Reply Regarding the 2-stage test design, we applied in the CCTG HN.6 study the following stepwise test procedure (Figure 1 by Wang et al), which controls the overall type I error rate at 5% used to analyze progression-free survival (PFS):

http://ift.tt/2uBEqsn